Edwards Lifesciences Corp
EW80.500USD
0.0000.00%
Close 01/29, 16:00（ET）Quotes delayed by 15 min
46.75BMarket Cap
34.28P/E TTM
More Details of Edwards Lifesciences Corp Company
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Edwards Lifesciences Corp Info
Ticker SymbolEW
Company nameEdwards Lifesciences Corp
IPO dateMar 27, 2000
CEOZovighian (Bernard J)
Number of employees15800
Security typeOrdinary Share
Fiscal year-endMar 27
AddressOne Edwards Way
CityIRVINE
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code92614
Phone19492502500
Websitehttps://www.edwards.com
Ticker SymbolEW
IPO dateMar 27, 2000
CEOZovighian (Bernard J)
Company Executives of Edwards Lifesciences Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
By BusinessUSD
Name
Revenue
Proportion
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
By RegionUSD
Name
Revenue
Proportion
United States
907.50M
58.43%
Europe
387.90M
24.98%
Rest of the world
167.60M
10.79%
Japan
90.10M
5.80%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
Shareholding Stats
Updated: Sat, Jan 10
Updated: Sat, Jan 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
Other
71.62%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
Other
71.62%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.83%
Investment Advisor/Hedge Fund
30.96%
Hedge Fund
3.47%
Pension Fund
2.27%
Research Firm
2.17%
Bank and Trust
1.96%
Sovereign Wealth Fund
1.37%
Individual Investor
0.93%
Endowment Fund
0.83%
Other
9.21%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
2452
517.66M
93.53%
--
2025Q3
2537
517.80M
94.00%
-1.50M
2025Q2
2614
519.17M
94.35%
-5.19M
2025Q1
2599
525.51M
93.66%
-25.15M
2024Q4
2585
522.16M
89.45%
+17.15M
2024Q3
2546
504.88M
87.53%
-10.03M
2024Q2
2541
515.71M
87.77%
+1.93M
2024Q1
2555
513.21M
86.74%
-8.92M
2023Q4
2556
503.19M
87.55%
-12.35M
2023Q3
2509
516.79M
88.03%
-521.37K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
70.09M
12.08%
+359.01K
+0.51%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
30.52M
5.26%
-370.16K
-1.20%
Sep 30, 2025
State Street Investment Management (US)
25.62M
4.41%
-14.75K
-0.06%
Sep 30, 2025
Wellington Management Company, LLP
20.80M
3.59%
+977.93K
+4.93%
Sep 30, 2025
JP Morgan Asset Management
17.92M
3.09%
-2.17M
-10.80%
Sep 30, 2025
Jennison Associates LLC
13.96M
2.41%
+2.29M
+19.60%
Sep 30, 2025
Fidelity Management & Research Company LLC
13.03M
2.25%
+10.73M
+466.56%
Sep 30, 2025
Geode Capital Management, L.L.C.
12.84M
2.21%
+114.73K
+0.90%
Sep 30, 2025
Walter Scott & Partners Ltd.
9.96M
1.72%
+1.05M
+11.73%
Sep 30, 2025
Union Investment Privatfonds GmbH
8.60M
1.48%
+19.17K
+0.22%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares U.S. Medical Devices ETF
4.72%
Future Fund Long/Short ETF
3.86%
iShares Health Innovation Active ETF
3.65%
Global X Aging Population ETF
3.31%
Acruence Active Hedge US Equity ETF
2.58%
First Trust Indxx Medical Devices ETF
2.23%
State Street SPDR S&P Health Care Equipment ETF
1.88%
JPMorgan Healthcare Leaders ETF
1.8%
PGIM Jennison Better Future ETF
1.78%
ROBO Global Healthcare Technology & Innovation ETF
1.73%
View more
iShares U.S. Medical Devices ETF
Proportion4.72%
Future Fund Long/Short ETF
Proportion3.86%
iShares Health Innovation Active ETF
Proportion3.65%
Global X Aging Population ETF
Proportion3.31%
Acruence Active Hedge US Equity ETF
Proportion2.58%
First Trust Indxx Medical Devices ETF
Proportion2.23%
State Street SPDR S&P Health Care Equipment ETF
Proportion1.88%
JPMorgan Healthcare Leaders ETF
Proportion1.8%
PGIM Jennison Better Future ETF
Proportion1.78%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.73%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Ex-dividend Date
Type
Ratio
May 07, 2020
Split
1→3
Date
Ex-dividend Date
Type
Ratio
May 07, 2020
Split
1→3
